Expert Wegovy vs Mounjaro Dose Comparison & Purchase Guide
Understanding Wegovy and Mounjaro Doses: Online Purchase Options UK
When comparing Wegovy and Mounjaro doses for online purchase in the UK, understanding the fundamental differences helps inform your treatment choice. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones, whilst Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist offering a different mechanism of action. Both prescription-only medicines require careful dose escalation over several months, but their specific schedules and maximum doses differ significantly.
EverydayMeds provides both treatments through our GPhC-registered online pharmacy (#9012878), ensuring you receive genuine manufacturer products whether you choose Wegovy or Mounjaro. Our clinical assessment process evaluates your suitability for either treatment, with qualified prescribers reviewing your individual circumstances to determine the most appropriate option. The convenience of online purchasing eliminates multiple pharmacy visits whilst maintaining the highest safety standards through proper medical oversight.
Wegovy and Mounjaro Doses: UK Pricing and Bundle Options
Wegovy doses at EverydayMeds start with the 0.25mg pen at £79.99 for weeks 1-4, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose (£209.99). Our Getting Started bundles provide convenient progression options, such as the Intro Duo combining 0.25mg and 0.5mg pens for £169.99, ideal for your first 8 weeks of treatment. For established users, the Ultimate Stability Trio offers three 2.4mg maintenance pens for £649.99, ensuring continuous supply without frequent reordering.
Bundle pricing reflects convenience rather than pure savings, eliminating the need for multiple orders and ensuring treatment continuity. New customers benefit from discount code FIRST40 applied at checkout, whilst returning customers use code DOSE25 to reach these final prices. Both Wegovy and Mounjaro require similar investment levels, though Mounjaro's different dosing schedule may influence your monthly costs depending on individual titration speed and maintenance requirements.
Clinical Evidence for Wegovy and Mounjaro Dose Effectiveness
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 study (Wilding et al., NEJM, 2021). The STEP trial programme demonstrated consistent results across different populations, with STEP 5 showing sustained clinically studied weight loss at 2 years when treatment continued. Individual results may vary significantly based on adherence to dose escalation schedules and lifestyle modifications.
Mounjaro's SURMOUNT trials showed different weight loss profiles, though direct comparison between trial results isn't appropriate due to varying study designs and participant populations. Both treatments require commitment to the full dose escalation schedule and maintenance phases to achieve optimal outcomes. Clinical evidence supports both medicines as effective tools when used alongside comprehensive lifestyle interventions.
How Wegovy and Mounjaro Doses Work Differently
Wegovy's semaglutide targets GLP-1 receptors exclusively, reducing appetite and promoting satiety after smaller meals by mimicking natural incretin hormones released after eating. This mechanism works primarily on brain appetite centres, potentially reducing food cravings and extending feelings of fullness between meals. The dose escalation from 0.25mg to 2.4mg allows gradual adaptation to these effects whilst minimising potential gastrointestinal side effects. Mounjaro's tirzepatide provides dual action through both GIP and GLP-1 receptors, offering a different approach to appetite regulation and metabolic control. The choice between single and dual receptor targeting depends on individual response patterns and clinical assessment outcomes.
Wegovy and Mounjaro Doses: Streamlined Online Ordering Process
Purchasing Wegovy or Mounjaro doses through EverydayMeds involves a straightforward 3-step process designed for safety and convenience. Complete our 3-minute online clinical assessment covering medical history, current medications, and treatment goals, providing qualified prescribers with essential information for dose selection. Following assessment submission, our medical team reviews your application within standard 3 working days (express 24-hour service available), determining treatment suitability and appropriate starting doses. Once approved, your chosen Wegovy or Mounjaro pens are dispatched via next-day delivery using specialist cold-chain transport to maintain optimal storage conditions. This process ensures clinical oversight whilst eliminating traditional pharmacy queues and scheduling constraints common with high-demand weight management treatments.
Storage Considerations for Wegovy and Mounjaro Doses
Wegovy storage requirements offer practical advantages for UK customers, maintaining stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's maximum 21-day room temperature limit. Both treatments require refrigeration at 2-8°C before first use, but Wegovy's extended temperature tolerance provides greater flexibility for travel, work schedules, or temporary storage challenges. The FlexTouch pen design for Wegovy enables precise dose delivery through pre-filled, single-use injection pens that eliminate dosing errors during escalation phases. Understanding these storage differences helps inform treatment choice, particularly for customers with irregular schedules or frequent travel requirements that might impact medication storage consistency.
Wegovy vs Mounjaro Doses: UK Regulatory and Supply Considerations
Both Wegovy and Mounjaro doses are subject to MHRA regulation as prescription-only medicines, with Wegovy maintaining additional monitoring status (Black Triangle ▼) requiring enhanced safety reporting. EverydayMeds sources directly from licensed UK distributors, ensuring authentic Novo Nordisk Wegovy and Eli Lilly Mounjaro products rather than imported alternatives with uncertain provenance. Supply consistency varies between manufacturers, though our established relationships help maintain stock availability across the complete dose range for both treatments.
Recent MHRA approval of Wegovy 7.2mg doses (6 January 2026) provides future escalation options for patients requiring higher maintenance doses, though this strength isn't yet available through EverydayMeds pending full supply chain implementation. Choosing between Wegovy and Mounjaro doses often depends on supply reliability, storage preferences, and individual response to different receptor targeting mechanisms rather than pure efficacy considerations.
Making Your Choice: Expert Support for Wegovy and Mounjaro Doses
Both Wegovy and Mounjaro are available from EverydayMeds, with qualified prescribers helping determine which treatment aligns best with your medical history, lifestyle requirements, and weight management goals. Our clinical team provides ongoing support throughout dose escalation phases, monitoring progress and adjusting treatment plans based on individual response patterns. Starting your assessment today with discount codes FIRST40 (new customers) or DOSE25 (returning customers) ensures you receive expert guidance whilst accessing competitive pricing on genuine manufacturer products. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and discover which treatment option suits your individual circumstances best through proper medical evaluation and ongoing prescriber support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
